17,261 trials
Essential Tremor
Primary: Normalized Accelerometric Tremor Power, Dominant Hand, 80min After Administration, Weighted Condition — 0.669; 0.798 ratio — p==0.345
Arthritis, Rheumatoid
Primary: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 — 20; 36; 38; 45 participants
Hyperoxaluria
Primary: Urinary Oxalate Creatinine Ratio — 68.6; 38.7; 49.6; 34.7 mg/g — p=0.027
Dry Eye Syndrome · Dry Eye
Primary: Corneal Staining (Inferior Region) in the Worst Eye in the Controlled Adverse Environment (CAE) Model, Which is a Regulated Environmental Setting Aimed at Exacerbating…
HIV-1
Primary: The Number of Patients With Treatment-emergent Adverse Events (TEAEs) — 89; 0; 5; 14 Patients
Non-alcoholic Fatty Liver Disease
Primary: Liver Fat Content — 8.38; 7.72; 8.50; 7.29 percentage of liver fat content — p=0.94
Melanoma · Neoplasm Metastasis
Primary: Clinical Response — 0; 0; 0; 0 Participants
Breast Cancer
Primary: Response Rate — 21 participants
Congestive Heart Failure · Cardiomyopathy
Primary: Change in Left Ventricular (LV) Volume Index at 8 Weeks — -5.2; 5.8; -10.0; 6.1 ml/m^2 — p=0.004
Breast Cancer
Primary: Change From Baseline in 18F-FLT-PET Mean Standardized Uptake Value (SUVmean) After the First Cycle of Standard of Care (SOC) Neo-adjuvant Chemotherapy. — 2.79; 1.78…
Breast Cancer
Primary: Number of Participants Who Remained Alive Without Evidence of Recurrence as a Measure of Tolerability of Adjuvant Nab Paclitaxel — 63 Participants
Acute Deep Venous Thrombosis of the Lower Extremity
Primary: Number of Participants With Restored Venous Function — 28 participants
HIV Infections · Lipodystrophy
Primary: Baseline to 24-week Change in Visceral Adipose Tissue Volume (cm^2) — -6.6; 1.8 cm^2 — p=0.52
Psoriasis
Primary: Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score at Week 12 — 25.00; 40.82; 66.67; 2.00 percentage of…
Contiguous Stage II Adult Diffuse Large Cell Lymphoma · Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma · Stage III Adult Diffuse Large Cell Lymphoma
Primary: Progression-free Survival at 1 Year — 77 percentage of participants